fig5

Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance

Figure 5. Effects of docetaxel on signaling in MCF7 and MCF7/HT cells. (A) - Representative immunoblotting images of MCF7 and MCF/HT cells with antibodies against cleaved PARP, Bcl-2, Bad, p-ERK 1/2, ERK 1/2, p-S6K, S6K, and cyclin D1; the cells were treated with docetaxel (DCT) for 24 h and then subjected to immunoblot analysis. Antibodies against α-tubulin were used as loading control. (B) - Densitometry for immunoblotting data (n = 3); *P < 0.05 vs. corresponding control cells; #P < 0.05 vs. corresponding DCT-treated MCF7 cells.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/